The world of medical diagnostics is witnessing a groundbreaking innovation that could revolutionize the fight against Ebola virus disease. Professor Yasutoshi Kido and his team at Osaka Metropolitan University (OMU) have developed a rapid, portable diagnostic system capable of detecting the Bundibugyo Ebola virus within just 30 minutes. This cutting-edge technology, funded by the Global Health Innovative Technology Fund (GHIT Fund), is a testament to the power of international collaboration and rapid response in the face of infectious disease outbreaks.
A Race Against Time
The development of this diagnostic system is particularly timely, given the recent Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo and Uganda, declared a "Public Health Emergency of International Concern" (PHEIC) by the World Health Organization (WHO) on May 16, 2026. The Bundibugyo virus, a distinct member of the Ebolavirus genus, poses unique challenges in diagnosis due to its differences from the more commonly known Ebola virus (EBOV).
In outbreak areas, rapid testing and isolation of suspected cases are crucial. However, the current landscape presents significant obstacles, including specimen transport issues, limited power supply, and a shortage of testing personnel and biosafety measures. Point-of-care testing (POCT) is essential in such scenarios, enabling on-site testing without the need for advanced laboratory facilities.
The 100-Day Mission
The research team's development framework aligns with the ambitious "100-Day Mission" initiative, which aims to have diagnostic tools, treatments, and vaccines ready for deployment within 100 days of identifying a new infectious disease threat. This mission is a call to action for the global scientific community to collaborate and respond swiftly to emerging health crises.
The OMU researchers, in partnership with K.K. DNAFORM and the National Institute for Biomedical Research (INRB), have achieved remarkable progress in just 40 days, producing a prototype test kit for Bundibugyo virus detection. Initial laboratory testing has confirmed the kit's performance, meeting the target sensitivity and specificity criteria.
GenPad: A Smart, Portable Solution
At the heart of this innovation is the GenPad smart BDBV portable rapid diagnostic system, which utilizes K.K. DNAFORM's SmartAmp isothermal PCR technology. This platform is designed for portability, enabling testing even in remote outbreak sites without reliable power infrastructure. The system's key features include:
- High Sensitivity: The prototype meets the target limit of detection (LOD) of ≤200 copies per cartridge, ensuring accurate and early detection.
- Specificity: Initial testing showed no cross-reactivity with a panel of 86 microbial species, ensuring specificity and reducing false positives.
- Portability: Weighing only 460 grams, the device is lightweight and easy to transport.
- Battery-Powered: With a 7.2 VDC, 21.6 Wh battery, it can perform eight tests on a single charge, making it ideal for field use.
- Rapid Results: Results are available within 30 minutes of blood collection, enabling swift decision-making.
- User-Friendly Design: Fully sealed cartridges simplify sample handling and reduce exposure risk, making it safer for healthcare workers.
- Scalability: Multiple devices can be clustered to test multiple samples simultaneously, increasing efficiency.
A Collaborative Endeavor
The development of this technology is a testament to the power of collaboration. OMU's research background in infectious diseases, including mpox, and its partnership with INRB and K.K. DNAFORM, have been instrumental in this rapid development. The support from the Acquisition, Technology & Logistics Agency's Security Technology Research Promotion Program has further enabled the establishment of a system to develop and manufacture GenPad cartridges within a short timeframe.
Looking Ahead
The research team's future plans include:
- Performance Validation: Further validation using mock samples and clinical performance testing in the Democratic Republic of the Congo.
- Multiplex Testing: Development of a multiplex version to differentiate Bundibugyo, Ebola, and Sudan viruses within a single cartridge.
- Regulatory Approval: Preparation of data for potential WHO Emergency Use Listing and other emergency regulatory pathways.
This project exemplifies OMU's commitment to advancing medical research and technology, fostering collaborations with industry, academia, government, and international organizations to combat infectious diseases. The rapid development of this diagnostic system is a promising step towards better preparedness and response to Ebola virus outbreaks, ultimately improving global health security.
